Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer

Edwards, Stephen M., Dunsmuir, William D., Gillett, Cheryl E., Lakhani, Sunil R., Corbishley, Catherine, Young, Martin, Kirby, Roger S., Dearnaley, David P., Dowe, Anna, Ardern-Jones, Audrey, Kelly, Jo, CRC/BPG UK Fmilial Prostate Cancer Study Collaborators, Spurr, Nigel, Barnes, Diana M. and Eeles, Rosalind A. (1998) Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. International Journal of Cancer, 78 1: 1-7. doi:10.1002/(SICI)1097-0215(19980925)78:1<1::AID-IJC1>3.0.CO;2-U

Author Edwards, Stephen M.
Dunsmuir, William D.
Gillett, Cheryl E.
Lakhani, Sunil R.
Corbishley, Catherine
Young, Martin
Kirby, Roger S.
Dearnaley, David P.
Dowe, Anna
Ardern-Jones, Audrey
Kelly, Jo
CRC/BPG UK Fmilial Prostate Cancer Study Collaborators
Spurr, Nigel
Barnes, Diana M.
Eeles, Rosalind A.
Title Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer
Journal name International Journal of Cancer   Check publisher's open access policy
ISSN 0020-7136
Publication date 1998-09
Sub-type Article (original research)
DOI 10.1002/(SICI)1097-0215(19980925)78:1<1::AID-IJC1>3.0.CO;2-U
Volume 78
Issue 1
Start page 1
End page 7
Total pages 7
Place of publication Hoboken, NJ, United States
Publisher John Wiley & Sons
Language eng
Abstract Many epidemiological studies have reported an association between breast and prostate cancer. BRCA2 functions as a tumour-suppressor gene in about 35% of large familial breast-cancer clusters; its role in the pathogenesis of sporadic breast cancer is less clear. We have evaluated immunohistochemical expression of BRCA2 protein and allelic loss of markers at the BRCA2 locus in tissue derived both from sporadic and from familial cases of prostate cancer. Immunohistochemical analysis was performed in 167 paraffin-embedded archival specimens. Normal prostate and 75% (120/160) of prostate-cancer tissue did not express BRCA2 protein. However, 25% (40/160) of cancer cases did express patchy staining; of these, 17% (27/160) expressed positive nuclear staining in normal glandular tissue adjacent to tumour (either in addition to, or, independent of tumour). Allelic loss is the hallmark of a tumour-suppressor gene. Markers flanking (D13S267, D13S260) and within (D13S171) the BRCA2 gene indicated allelic loss in at least one locus in 23% (17/73) of tumours analyzed. There was no difference in the rates of allelic loss between sporadic and familial tumours, nor was there any association between immunohistochemical staining and allelic loss. Although immunohistochemical staining provided no useful prognostic information, allelic loss at BRCA2 was shown in univariate analysis to be associated with poorer survival (log-rank test, p = 0.046).
Keyword Comparative genomic hybridization
Breast cancer
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ
Additional Notes Article first published online: 6 January 1999.

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Chemistry and Molecular Biosciences
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 22 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 21 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 22 Jun 2011, 12:26:23 EST by System User on behalf of Discipline of Molecular and Cellular Pathology